Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of MK-1654 in Healthy Adults Experimentally Inoculated With RSV
2018-003347-28Phase 2Unknown
- Sponsor
- Merck & Co.
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of clesrovimab-cfor in respiratory syncytial virus disease (RSV) (5 arms), sponsored by Merck & Co. Primary endpoint: Area Under Viral Load-time Curve (VL-AUC). Status: unknown.
02
Drugs
clesrovimab-cfor
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2018-003347-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003347-28.